Int J STD AIDS

This cross-sectional study of 3212 pregnant women assessed the field performance, acceptability, and feasibility of two dual HIV/syphilis rapid diagnostic tests, the Chembio DPP HIV-syphilis Assay and the SD Bioline HIV/syphilis Duo in antenatal clinics. Sensitivity and specificity for HIV and syphilis were calculated compared to the rapid Determine HIV-1/2 with Uni-Gold to confirm positive results for HIV and the Treponema pallidum particle agglutination assay for syphilis. RPR titers 651:4 were used to define active syphilis detection. Acceptability and feasibility were assessed using self-reported questionnaires. For Chembio, the HIV sensitivity was 90.6% (95%CI\u2009=\u200987.4, 93.0) and specificity was 97.2% (95%CI\u2009=\u200996.2, 97.8); syphilis sensitivity was 68.6% (95%CI\u2009=\u200961.9, 74.6) and specificity was 98.5% (95%CI\u2009=\u200997.8, 98.9). For SD Bioline, HIV sensitivity was 89.4% (95%CI\u2009=\u200986.1, 92.0) and specificity was 96.3% (95%CI\u2009=\u200995.3, 97.1); syphilis sensitivity was 66.2% (95%CI\u2009=\u200959.4, 72.4) and specificity was 97.2% (95%CI\u2009=\u200996.4, 97.9). Using the reference for active syphilis, syphilis sensitivity was 84.7% (95%CI\u2009=\u200976.1, 90.6) for Chembio and 81.6% (95%CI\u2009=\u200972.7, 88.1) for SD Bioline. Both rapid diagnostic tests were assessed as highly acceptable and feasible. In a field setting, the performance of both rapid diagnostic tests was comparable to other published field evaluations and each was rated highly acceptable and feasible. These findings can be used to guide further research and proposed scale up in antenatal clinic settings.20182020-03-01T00:00:00Z001/World Health Organization/InternationalCC999999/Intramural CDC HHS/United StatesNU2GGH001920/PEPFAR/PEPFAR/United States30472926PMC6751556731